Paulo Verardi, a virologist at the University of Connecticut, stated that the Russian vaccine against coronavirus infection Sputnik V will play an important role in the fight against pandemics worldwide due to its advantages.
“Unlike other recombinant COVID-19 vaccines based on the adenovirus vector, Sputnik V is based on a prime-boost immunization scheme using two different recombinant vectors: first the [human] adenovirus 26th [serotype] and then the adenovirus 5th [serotype],” the specialist said. Prime-boost immunization refers to a two-stage vaccination: the first dose triggers an immune response and the second dose enhances it.
Verardi noted that such a regimen “prevents immunity developed against the first vector from interfering with the second dose of vaccine, which is an obvious advantage.”
Earlier, the medical journal Lancet reported that the results of phase III clinical trials of the Russian vaccine Sputnik V demonstrated 91.6 percent efficacy against coronavirus. A total of 19,866 people participated in testing the vaccine.
“Sputnik V” was developed by the Russian Gamaleya Research Center and became the world’s first officially registered vaccine against coronavirus. Later, the Russian Ministry of Health registered another drug, EpiVacCorona, developed by Rospotrebnadzor’s Vektor center.